X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - FINANCIALPOST.COM - A La Une - 20/Aug 11:01

XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024

Health consequences of over active xanthine oxidase may accelerated PKD progression CALGARY, Alberta, Aug. 20, 2024 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the acceptance […]

Articles similaires

Sorry! Image not available at this time

Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

drugs.com - 03/Sep 01:09

LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...

Sorry! Image not available at this time

Aethlon Medical to Present at the Life Sciences Investor Forum September 19th

financialpost.com - 13/Sep 12:38

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com SAN...

Sorry! Image not available at this time

Aethlon Medical to Present at the Life Sciences Investor Forum September 19th

financialpost.com - 13/Sep 12:38

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com SAN...

Sorry! Image not available at this time

Vico Therapeutics Announces Positive Interim Phase 1/2a Clinical Data of VO659 in Treatment of Huntington's Disease

drugs.com - 14/Sep 05:09

LEIDEN, Netherlands, Sept. 13, 2024. Vico Therapeutics B.V., a clinical-stage genetic medicines company developing therapies for severe neurological...

Sorry! Image not available at this time

TC BioPharm to begin Proof of Concept preclinical studies for its lead therapeutic TCB 008 to treat monkey pox

pharmabiz.com - 09/Sep 00:00

TC BioPharm (Holdings) PLC (TC BioPharm), a clinical stage biotechnology company developing platform allogeneic gamma─delta T cell therapies for...

Sorry! Image not available at this time

Interstitial Cystitis Clinical Trials 2024 (Updated): FDA Approvals, Medication, Pipeline, Therapies, Mechanism of Action, ROA and Companies by DelveInsight

mountaintoday.in - 15/Sep 08:16

Interstitial Cystitis Clinical Trials Interstitial Cystitis companies are Seikagaku Corporation, UCB, Alivio Therapeutics, Merck, Teva Pharmaceutical,...

Sorry! Image not available at this time

Gene Therapies For Cardiomyopathies Market Growth Anticipated by 2032 | Companies includes Lexeo Therapeutics, expected to boost the market

mountaintoday.in - 12/Sep 07:49

Gene Therapies For Cardiomyopathies Market Gene Therapies For Cardiomyopathies Market Growth is expected due to increased interest from companies in...

Sorry! Image not available at this time

Gene Therapies For Cardiomyopathies Market Growth Anticipated by 2032 | Companies includes Lexeo Therapeutics, expected to boost the market

mountaintoday.in - 12/Sep 07:49

Gene Therapies For Cardiomyopathies Market Gene Therapies For Cardiomyopathies Market Growth is expected due to increased interest from companies in...

Sorry! Image not available at this time

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

financialpost.com - 03/Sep 20:34

VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing...

Sorry! Image not available at this time

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

financialpost.com - 03/Sep 20:34

VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing...

Les derniers communiqués